Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.47 |
| ▸ | PPARA | Q07869 | 13/20 | 0.47 |
| ▸ | PPARD | Q03181 | 8/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065602 | 0.94 | PPARG (0.49) | PPARGPPARAPPARDPTPN1 | |
| SCHEMBL4057835 | 0.88 | PPARG (0.45) | PPARGPPARAPPARDALOX5 | |
| SCHEMBL4061332 | 0.84 | PPARA (0.48) | PPARGPPARAPPARDPTPN1 | |
| SCHEMBL4065023 | 0.84 | PPARA (0.46) | PPARGPPARAPPARD | |
| SCHEMBL4067544 | 0.84 | PPARA (0.47) | PPARGPPARAPPARDPTPN1 | |
| SCHEMBL4062322 | 0.81 | PPARG (0.52) | PPARGPPARAPPARD | |
| SCHEMBL4067991 | 0.80 | PPARG (0.67) | PPARGPPARAPPARDPTPN1 | |
| SCHEMBL4062648 | 0.79 | PPARG (0.54) | PPARGPPARAPPARD | |
| SCHEMBL4057020 | 0.78 | PPARG (0.40) | PPARGPPARAPPARDPTPN1PTPN6 | |
| SCHEMBL4064554 | 0.77 | PPARA (0.55) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1666472-B1 | PHENYLACETIC ACID DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | ONO PHARMACEUTICAL CO (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-7560475-B2 | Phenylacetic acid derivative, process for producing the same, and use | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20070105868-A1 | Phenylacetic acid derivative, process for producing the same, and use | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1666472-A1 | PHENYLACETIC ACID DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105868-A1 | Phenylacetic acid derivative, process for producing the same, and use | PPARA, PPARD, PPARG | PPARG 3/4885PPARA 1/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.